Safety and Efficacy of CollaRx� Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy
Information source: Innocoll
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Herniorrhaphy; Postoperative Pain; Inguinal Hernia
Intervention: Bupivacaine Collagen Sponge (Drug); Placebo collagen Sponge (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Innocoll Official(s) and/or principal investigator(s):
David Prior, Study Director, Affiliation: Innocoll
Summary
This study will assess pain intensity for the first 72 hrs after after aggravated movement
(cough)following open laparotomy inguinal herniorrhaphy in patient who receive either the
CollaRx Bupivacaine implant or a plain collagen sponge.
Clinical Details
Official title: A Phase II, Randomized, Single Dose, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety Profile of the CollaRx® Bupivacaine Implant (200 mg Bupivacaine Hydrochloride) in Men After Open Laparotomy Herniorrhaphy
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Sum of pain intensity (SPI) after aggravated movement (cough)
Secondary outcome: SPI after aggravated movement (cough)SPI and individual VAS PI score at rest Total use of opioid analgesia
Detailed description:
Inguinal herniorrhaphy is a common surgery; and common surgical methods used include
laparoscopic and open placement of synthetic mesh. The use of synthetic mesh can greatly
reduce the risk of hernia recurrence regardless of the method used for its placement.
Managing postoperative pain and preventing morbidity after open mesh herniorrhaphy remain
considerable medical challenges.
Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile.
Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a
thin flat sponge made out of collagen that comes from cow tendons and contains bupivacaine.
When inserted into a surgical site, the collagen breaks down and bupivacaine is released at
the site but very little is absorbed into the blood stream. The high levels of bupivacaine
at the surgical site may result in less pain for several days after surgery.
This study will assess pain intensity after surgery in patients who receive either the
CollaRx Bupivacaine implant or a plain collagen sponge.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Man ≥ 18 years
- Body mass index (BMI) ≥ 19 and ≤ 40 kg/m2.
- Has a planned unilateral inguinal herniorrhaphy (open laparotomy, tension free
technique) to be performed according to standard surgical technique under general
anesthesia.
Exclusion Criteria:
- Has a known hypersensitivity to amide local anesthetics, opioids, or bovine products.
- Scheduled for bilateral inguinal herniorrhaphy.
- Undergone a prior herniorrhaphy on the side scheduled for repair.
- Undergone major surgery within 3 mos of the scheduled herniorrhaphy.
- Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.
- Concomitantly uses antiarrhythmics (eg, amiodarone, lidocaine), propranolol, or
strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide
antibiotics and grapefruit juice).
- Used long acting analgesics within 24 hours of surgery. Short acting analgesics such
as acetaminophen may be used on the day of surgery but are subject to preoperative
restrictions for oral intake.
Locations and Contacts
Bellaire, Texas, United States
Additional Information
Starting date: December 2010
Last updated: September 2, 2014
|
